CTI Biopharma Corp. provided no details but faces limited options for Pixuvri (pixantrone) after a postmarketing phase III trial missed the primary endpoint of progression-free survival (PFS). The study was evaluating the small molecule in combination with Rituxan (rituximab, Roche Holding AG/Biogen Inc.) compared to gemcitabine plus rituximab in patients with aggressive B-cell non-Hodgkin lymphoma (NHL).